That's great news for Visx, since now they don't have to split PRK royalties with Summit, and legal/PPP expenses will drop.
LASE and ATCI may get FDA approval in late 98, and TLC (Nasdaq:LZRCF) is making an investment in LASE. TLC/LASE are working on a mobile business, like LVCI has been doing for a year.
LASE sells something like 15 lasers abroad per Q, and with TLC's endorsement, it looks like LASE will definitely sell a decent # per Q in U.S., since the U.S. market can handle another 400 systems over the next 5 years. The question is: will Visx be successful in collecting per-use fees on LASE and ATCI lasers, and if so, how much will LASE and ATCI pocket?
Also, is Visx working on a topography-based system? They acquired the Phoenix patents in 1997, which supposedly cover scanning and novel methods of charting corneal topography... |
